Evidence map›Paper›PMID 34041490›Full record

ArticleRSC medicinal chemistry2021

Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability.

Chiara Borsari, Erhan Keles, Andrea Treyer, Martina De Pascale, Paul Hebeisen, Matthias Hamburger, Matthias P Wymann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chiara BorsariDepartment of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.ORCID https://orcid.org/0000-0002-4688-8362
Erhan KelesDepartment of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.ORCID https://orcid.org/0000-0003-1201-9158
Andrea TreyerPharmaceutical Biology, Pharmacenter, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland.ORCID https://orcid.org/0000-0002-4533-7761
Martina De PascaleDepartment of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.ORCID https://orcid.org/0000-0002-7546-2766
Paul HebeisenDepartment of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.
Matthias HamburgerPharmaceutical Biology, Pharmacenter, University of Basel Klingelbergstrasse 50 4056 Basel Switzerland.ORCID https://orcid.org/0000-0001-9331-273X
Matthias P WymannDepartment of Biomedicine, University of Basel Mattenstrasse 28 4058 Basel Switzerland Matthias.Wymann@Unibas.ch.ORCID https://orcid.org/0000-0003-3349-4281

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highly selective mTOR inhibitors have been discovered through the exploration of the heteroaromatic ring engaging the binding affinity region in mTOR kinase. Compound

Identifiers

PMID34041490
PMCPMC8128076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.